LENZ Therapeutics, Inc.
LENZ
$38.79
-$0.89-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.76% | 100.20% | 71.59% | 126.98% | 219.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.29% | 5.24% | -39.07% | -34.84% | -4.06% |
| Operating Income | -17.45% | -5.24% | 39.07% | 34.84% | 4.06% |
| Income Before Tax | -40.55% | 12.19% | 47.00% | 45.90% | 30.37% |
| Income Tax Expenses | -- | -- | 100.56% | -- | -- |
| Earnings from Continuing Operations | -45.43% | 12.19% | 46.60% | 45.90% | 30.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.43% | 12.19% | 46.60% | 45.90% | 30.37% |
| EBIT | -17.45% | -5.24% | 39.07% | 34.84% | 4.06% |
| EBITDA | -17.47% | -5.05% | 39.16% | 34.87% | 4.15% |
| EPS Basic | -32.64% | 84.95% | 96.18% | 96.09% | 94.68% |
| Normalized Basic EPS | -13.76% | 84.95% | 96.21% | 96.09% | 94.01% |
| EPS Diluted | -32.64% | 84.95% | 96.18% | 96.09% | 94.68% |
| Normalized Diluted EPS | -13.76% | 84.95% | 96.21% | 96.09% | 94.01% |
| Average Basic Shares Outstanding | 9.65% | 483.48% | 1,297.34% | 1,285.07% | 1,209.10% |
| Average Diluted Shares Outstanding | 9.65% | 483.48% | 1,297.34% | 1,285.07% | 1,209.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |